Investment analysts at HC Wainwright initiated coverage on shares of Vera Therapeutics (NASDAQ:VERA - Get Free Report) in a report released on Monday, Marketbeat reports. The firm set a "buy" rating and a $75.00 price target on the stock. HC Wainwright's price target indicates a potential upside of 244.51% from the stock's previous close. HC Wainwright also issued estimates for Vera Therapeutics' Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($3.18) EPS, FY2026 earnings at ($2.32) EPS, FY2027 earnings at $0.83 EPS, FY2028 earnings at $3.30 EPS and FY2029 earnings at $5.37 EPS.
Several other research analysts also recently commented on VERA. Wolfe Research began coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective on the stock. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target on the stock. Guggenheim increased their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $63.80.
View Our Latest Analysis on VERA
Vera Therapeutics Stock Performance
NASDAQ:VERA traded down $0.26 on Monday, hitting $21.77. The stock had a trading volume of 1,262,456 shares, compared to its average volume of 779,548. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -8.34 and a beta of 1.28. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The business's 50-day simple moving average is $24.22 and its two-hundred day simple moving average is $34.72. Vera Therapeutics has a 52-week low of $18.53 and a 52-week high of $51.61.
Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the company posted ($0.56) EPS. As a group, research analysts predict that Vera Therapeutics will post -2.89 earnings per share for the current year.
Hedge Funds Weigh In On Vera Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VERA. SG Americas Securities LLC raised its holdings in shares of Vera Therapeutics by 116.7% during the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock worth $857,000 after acquiring an additional 10,916 shares in the last quarter. Barclays PLC lifted its position in Vera Therapeutics by 94.1% during the third quarter. Barclays PLC now owns 85,395 shares of the company's stock valued at $3,774,000 after purchasing an additional 41,394 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Vera Therapeutics in the 4th quarter worth $2,948,000. Victory Capital Management Inc. increased its holdings in shares of Vera Therapeutics by 515.0% in the 4th quarter. Victory Capital Management Inc. now owns 235,267 shares of the company's stock worth $9,949,000 after buying an additional 197,014 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its position in shares of Vera Therapeutics by 44.2% during the 4th quarter. Teacher Retirement System of Texas now owns 12,860 shares of the company's stock valued at $544,000 after buying an additional 3,942 shares in the last quarter. 99.21% of the stock is owned by institutional investors.
About Vera Therapeutics
(
Get Free Report)
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Further Reading
Before you consider Vera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.
While Vera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
